News at CenExel
Administrating and Training on the Placebo-Control Reminder Script: A Deeper Dive Into the Tool’s Psychometric Properties
CenExel is proud to highlight the poster we're presenting at the Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP), May 2023, Miami, FL. ABSTRACT Introduction: Placebo and nocebo responses continue to hinder potential treatment effects...
Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age
CenExel is proud to announce the publication of the work of Kimball A. Johnson, MD, from CenExel iResearch, in the New England Journal of Medicine. Dr. Johnson participated in a study of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age. Other contributors included Evan J. Anderson, MD, C. Buddy Creech, MD, MPH, Vlasimir Berthaud, MD, MPH, Arin Piramzadian, DO, et al., for the KidCOVE Study Froup*
Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE)
CenExel is proud to announce the publication of the work of Brett English, PharmD, PhD, from CenExel’s Clinical Sciences team, in the Neurogastroenterology & Mortility journal. Dr. English participated in a study of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome. Other contributors included Lin Chang, Brooks D. Cash, Anthony Lembo, David C. Kunkel, Brett English, Beatriz Lindstrom, Guibao Gu, Sharon Skare, Kye Gilder, Stewart Turner, Fabio Cataldi, Donald Lipkis, and Tack Jan. The study aimed to assess the efficacy and safety of olorinab (IBS-D) and constipation (IBS-C).
The Placebo-Control Reminder Script and Supplementary Instrument Properties: Evaluation of Face and Content Validity
CenExel is proud to highlight the poster presented at the International Society for CNS Clinical Trials and Methodology (ISCTM) Annual Scientific Meeting, February 2023, Washington, DC. ABSTRACT Introduction: The Placebo-Control Reminder Script (PCRS) is an...
Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial
CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal, as co-author of the recent Cerevel Therapeutics study titled, Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial, published in The Lancet.
Primer on the Autonomic Nervous System – 4th Edition
This book provides a concise and accessible overview of autonomic neuroscience for students, scientists, and clinicians.
CenExel CNS Opens Center in Los Alamitos, California
Los Alamitos, November 29, 2022 /GlobeNewswire/ — CenExel CNS announces the grand opening of the newest clinical research facility in Los Alamitos, California. CenExel CNS has been operating clinical research centers in the area since 2000, and this site will be the...
CenExel Creates Clinical Sciences Business Unit
Salt Lake City, November 15, 2022 /GlobeNewswire/ — CenExel announces a new Clinical Sciences business unit, composed of early phase and translational medicine scientists, plus the broader network of CenExel therapeutic experts and key opinion leaders (KOLs),...
Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers.
Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry led-study in subjects with schizophrenia and healthy volunteers.